LB Pharmaceuticals (LBRX) investor relations material

Executive summary

• Focused on late-stage clinical development of LB-102 for schizophrenia, bipolar depression, and adjunctive MDD, with multiple ongoing and planned trials and a pipeline leveraging LB-102's potential as the first benzamide antipsychotic in the U.S.

• Initiated pivotal Phase 3 NOVA-2 trial for schizophrenia and Phase 2 ILLUMINATE-1 trial for bipolar depression in Q1 2026.

• Published positive Phase 2 NOVA-1 results in JAMA Psychiatry, showing direct cognitive benefits.

• No product revenue to date; operations funded by equity offerings, IPO proceeds, and a recent $100M private placement.

• Cash position of $365.6 million as of March 31, 2026, expected to fund operations into Q2 2029.

Financial highlights

• Net loss for Q1 2026 was $19.1M, compared to $5.3M in Q1 2025, driven by higher R&D and G&A costs.

• R&D expenses rose to $14.6M in Q1 2026 from $3.4M in Q1 2025, mainly due to increased clinical trial activity and headcount.

• G&A expenses increased to $7.5M from $3.0M year-over-year, driven by higher personnel, stock-based compensation, and professional fees.

• Cash, cash equivalents, and marketable securities totaled $365.6M as of March 31, 2026.

• Operating loss was $22.1M, up from $6.4M year-over-year.

Outlook and guidance

• Current cash resources expected to fund operations into Q2 2029 based on planned activities.

• Topline data from NOVA-2 in schizophrenia expected in H2 2027; ILLUMINATE-1 in bipolar depression in Q1 2028; adjunctive MDD trial topline in H1 2029.

• Anticipates continued operating losses and increased expenses as clinical development and organizational scaling continue.